TORONTO, Dec. 15, 2017 (GLOBE NEWSWIRE) — Canada House Wellness Group Inc. (CSE:CHV) (“Canada House” or the “Company”) is pleased to announce a limited time incentive program (the “Incentive Program”) applicable to holders of 1,275,000 common share purchase warrants issued by the Company on November 7, 2016 as part of convertible debenture units (the “2016 CD Warrants”) and to holders of 3,558,482 common share purchase warrants issued by the Company on February 24, 2015 (the “2015 Warrants” and, together with the 2016 CD Warrants, the “Eligible Warrants”). Holders of Eligible Warrants (“Warrant Holders”) who opt to take part in the Incentive Program will be able to exercise each Eligible Warrant for one common share (each a “Common Share“) of the Company at a price of $0.30 per Common Share. The exercise price of the 2015 Warrants and the 2016 CD Warrants, without giving effect to the Incentive Program, is $0.375 per Common Share and $0.40 per Common Share, respectively.

The Incentive Program commences immediately and expires at 5:00 p.m. (Toronto time) on January 5, 2018 (the “Expiry Time”).

The incentive program is not available to holders of common share purchase warrants issued by the Company on November 7, 2016 as part of equity units or to holders of any other common share purchase warrants of the Company aside from the Eligible Warrants.

To the extent that holders of Eligible Warrants take advantage of the opportunity to exercise their Eligible Warrants early, the proceeds from such exercises will fund working capital purposes. Eligible Warrants that remain unexercised following the Expiry Time will continue to be exercisable for Common Shares on their original terms.

Depending upon the number of Eligible Warrants exercised pursuant to the Incentive Program, the Company may:

  • receive gross proceeds of up to $1,450,044.60; and
  • issue up to 4,833,482 Common Shares.

The terms and conditions of the Incentive Program and the method of exercising Eligible Warrants pursuant to the Incentive Program are set forth in a letter and warrant exercise form which is being delivered to the registered address of each Warrant Holder. Warrant Holders who wish to participate in the Incentive Program will agree to exercise their Eligible Warrants and deliver the cash payment in respect thereof and other necessary documents as described in the letter to Warrant Holders. Warrant Holders who wish to receive a copy of the letter and warrant exercise form regarding the Incentive Program may do so by email to or by phone at 1 844 638 8387.

The Incentive Program is subject to the Company effecting all filings required by securities regulatory authorities and the Canadian Securities Exchange.

This news release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities described herein, and these securities will not be offered or sold in any jurisdiction in which their offer or sale would be unlawful. The securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the “1933 Act”), or any state securities laws of the United States. Accordingly, these securities will not be offered or sold to persons within the United States unless an exemption from the registration requirements of the 1933 Act and applicable state securities laws is available.

Canada House Wellness Group Inc.

Canada House is the parent company of Marijuana for Trauma Inc., Knalysis Technologies and Abba Medix Corp. The Company’s goal is to become a marketplace leader through strategic partnerships, mergers, and acquisitions to create a fully integrated cannabis therapy company. For more information please visit or

For further information, please contact:
Boom Capital Markets
Steve Low

Canada House Wellness Group, Inc.
Riley McGee

Cautionary Statement Regarding Forward-Looking Information. Certain statements within this news release pertaining to the Company constitute “forward‐looking statements”, within the meaning of applicable securities laws, including without limitation, statements regarding future estimates, business plans and/or objectives, sales programs, forecasts and projections, assumptions, expectations, and/or beliefs of future performance, are “forward‐looking statements”. Such “forward‐looking statements” involve known and unknown risks and uncertainties that could cause actual and future events to differ materially from those anticipated in such statements. Forward‐looking statements include, but are not limited to, statements with respect to the anticipated effects of the financing, regulatory changes, timeliness of government approvals for the granting of permits and licenses, changes in medical marijuana prices, actual operating performance of facilities, competition and other risks affecting the Company in particular and the medical marijuana industry generally, including those set out in the Company’s public disclosure record. The Company assumes no responsibility to update or revise forward‐looking information to reflect new events or circumstances unless required by law.

Neither the CSE nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.